Metoject pens replace prefilled syringes

Medac has launched Metoject PEN (methotrexate) a single-use prefilled pen for subcutaneous injection, to replace the existing syringe presentation.

Metoject is no longer indicated for Crohn's disease.
Metoject is no longer indicated for Crohn's disease.

The new prefilled pen device is available in the full range of existing doses and has the same colour coding as the syringe to distinguish between the different strengths.

It is indicated for the treatment of:

  • severe recalcitrant disabling psoriasis
  • severe psoriatic arthritis
  • polyarthritic forms of severe active juvenile idiopathic arthritis when the response to NSAIDs has been inadequate
  • active rheumatoid arthritis.

The Metoject pen device is not currently licensed for use in Crohn's disease.

View Metoject drug record

Further information: Medac

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more